|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant full length human thymidine phosphorylase (TP/PD-ECGF) protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1-2 µg/ml|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13542 targets Thymidine Phosphorylase in IHC (P) applications and shows reactivity with Human, mouse, and Rat samples.
The MA5-13542 immunogen is recombinant full length human thymidine phosphorylase (TP/PD-ECGF) protein.
Platelet-derived endothelial growth factor (PD-ECGF), same as thymidine phosphorylase (TP) or gliostatin. In the presence of inorganic orthophosphate, it catalyses the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
MA5-13542 was used in immunohistochemistry - paraffin section to identify biomarkers relevant to treatment outcomes in gastric cancer patients receiving adjuvant S-1 chemotherapy.
|Kim JY,Shin E,Kim JW,Lee HS,Lee DW,Kim SH,Lee JO,Kim YJ,Kim JH,Bang SM,Ahn SH,Park DJ,Lee JS,Lee JS,Kim HH,Lee KW||PloS one (10:null)||2015|
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
MA5-13542 was used in immunohistochemistry to study the efficacy and toxicity of combination chemotherapy in head and neck cancer.
|Won YW,Park YH,Ahn MJ,Do IG,Ko YH,Park K||Annals of oncology : official journal of the European Society for Medical Oncology (22:417)||2011|
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
MA5-13542 was used in immunohistochemistry to study combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
|Kim SJ,Han SW,Oh DY,Yi NJ,Kim YJ,Im SA,Yoon JH,Kang GH,Suh KS,Bang YJ,Jang JJ,Kim TY||Anticancer research (30:5245)||2010|
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
MA5-13542 was used in immunohistochemistry to study biomarkers for predicting the response to capecitabine and cisplatin combination chemotherapy in metastatic oesophageal squamous cell cancer
|Lee S,Park YH,Kim KH,Cho EY,Ahn YC,Kim K,Shim YM,Ahn JS,Park K,Im YH||British journal of cancer (103:845)||2010|
Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways.
MA5-13542 was used in immunohistochemistry to investigate the mechanism for the induction of thymidine phosphorylase by Epstein-Barr virus latent membrane protein 1
|Chen CC,Chen LC,Liang Y,Tsang NM,Chang YS||Cellular signalling (22:1132)||2010|
Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.
MA5-13542 was used in immunohistochemistry to investigate the expression level and role of thymidine kinase 1 and thymidine phosphorylase in non-small-cell lung carcinoma
|Brockenbrough JS,Morihara JK,Hawes SE,Stern JE,Rasey JS,Wiens LW,Feng Q,Vesselle H||The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (57:1087)||2009|
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
MA5-13542 was used in immunohistochemistry to identify the prognostic markers for advanced colorectal cancer chemotherapy
|Koopman M,Venderbosch S,van Tinteren H,Ligtenberg MJ,Nagtegaal I,Van Krieken JH,Punt CJ||European journal of cancer (Oxford, England : 1990) (45:1999)||2009|
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
MA5-13542 was used in immunohistochemistry to study the efficacy of combined cetuximab and modified FOLFOX6 treatment in a phase II gastric cancer trial
|Han SW,Oh DY,Im SA,Park SR,Lee KW,Song HS,Lee NS,Lee KH,Choi IS,Lee MH,Kim MA,Kim WH,Bang YJ,Kim TY||British journal of cancer (100:298)||2009|
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
MA5-13542 was used in immunohistochemistry to perform a phase II study of capecitabine and cisplatin chemotherapy in patients with advanced esophageal squamous cell carcinoma
|Lee J,Im YH,Cho EY,Hong YS,Lee HR,Kim HS,Kim MJ,Kim K,Kang WK,Park K,Shim YM||Cancer chemotherapy and pharmacology (62:77)||2008|
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
MA5-13542 was used in immunohistochemistry to investigate the association between neoadjuvants docetaxel and capecitabine and prostate cancer
|Friedman J,Dunn RL,Wood D,Vaishampayan U,Wu A,Bradley D,Montie J,Sarkar FH,Shah RB,Hussain M||The Journal of urology (179:911)||2008|
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
MA5-13542 was used in immunohistochemistry to study the role of thymidine phosphorylase expression in increased sensitivity to 5-fluorouracil in oropharyngeal cancer patients
|Ranieri G,Grammatica L,Patruno R,Zito AF,Valerio P,Iacobellis S,Gadaleta C,Gasparini G,Ribatti D||Journal of cellular and molecular medicine (11:362)||2007|
H pylori status and angiogenesis factors in human gastric carcinoma.
MA5-13542 was used in immunohistochemistry to study Helicobacter pylori antigen and angiogenesis factors in human gastric carcinoma
|Mangia A,Chiriatti A,Ranieri G,Abbate I,Coviello M,Simone G,Zito FA,Montemurro S,Rucci A,Di Leo A,Tommasi S,Berloco P,Xu JM,Paradiso A||World journal of gastroenterology (12:5465)||2006|
Upregulation of thymidine phosphorylase in chronic glomerulonephritis and its role in tubulointerstitial injury.
MA5-13542 was used in immunohistochemistry to study the upregulation of thymidine phosphorylase in chronic glomerulonephritis
|Wang EH,Goh YB,Moon IS,Park CH,Lee KH,Kang SH,Kang CS,Choi YJ||Nephron. Clinical practice (102:c133)||2006|
Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.
MA5-13542 was used in immunohistochemistry to study the prognostic value of thymidine phosphorylase in superficial bladder carcinoma
|Stavropoulos NE,Bouropoulos C,Ioachim E,Michael M,Hastazeris K,Tsimaris I,Kalogeras D,Liamis Z,Kafarakis V,Stefanaki S,Malamou-Mitsi V||International urology and nephrology (37:55)||2005|
Angiogenic growth factors in preinvasive breast disease.
MA5-13542 was used in immunohistochemistry to investigate the mechanism for the increased vascularity in preinvasive breast disease
|Heffelfinger SC,Miller MA,Yassin R,Gear R||Clinical cancer research : an official journal of the American Association for Cancer Research (5:2867)||1999|
Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
MA5-13542 was used in ELISA to investigate the systemic angiogenic status in patients with colorectal cancer undergoing bevacizumab therapy
|Brostjan C,Gebhardt K,Gruenberger B,Steinrueck V,Zommer H,Freudenthaler H,Roka S,Gruenberger T||Clinical cancer research : an official journal of the American Association for Cancer Research (14:2065)||2008|
Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
MA5-13542 was used in ELISA to investigate the importance of circulating angiogenic factors in dendritic cell-based cancer immunotherapy
|Brostjan C,Bayer A,Zommer A,Gornikiewicz A,Roka S,Benkö T,Yaghubian R,Jakesz R,Steger G,Gnant M,Friedl J,Stift A||Cancer (98:2291)||2003|